DexCom Q2 Adj $0.34 Beats $0.23 Estimate, Sales $871.30M Beat $841.62M Estimate
Portfolio Pulse from Happy Mohamed
DexCom (NASDAQ:DXCM) reported Q2 earnings of $0.34 per share, beating the analyst consensus estimate of $0.23 by 47.83%. This is a 100% increase from the same period last year. The company also reported quarterly sales of $871.30 million, beating the analyst consensus estimate of $841.62 million by 3.53%. This is a 25.87% increase from the same period last year.
July 27, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DexCom's Q2 earnings and sales exceeded analyst estimates, indicating strong financial performance. This could potentially lead to a positive impact on the company's stock price in the short term.
DexCom's Q2 earnings and sales have significantly exceeded analyst estimates, which is a strong indicator of the company's financial performance. This positive financial news could potentially lead to increased investor confidence and a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100